IL15 and acute graft versus host disease: Similarly, the 180-day cumulative incidence of grade II–IV acute GVHD was 25% in patients with day 14 IL-15 levels>median (10.5 pg/mL) versus 33% in patients with day 14 IL-15 levels ≤ median (P = 0.8) (Figure 3D).